Jessa E. Flores
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessa E. Flores has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jed Allyn T. Hernandez
Inje University
2 shared publications - Maria Victoria Faith Garcia
Inje University
2 shared publications Alessandra Beatrice L. Donado
1 shared publicationHyoung Kyu Kim
Inje University
1 shared publicationJin Han
1 shared publication- Jin Han
Basic Research Laboratory, Department of Physiology, College of Medicine, Smart Marine Therapeutic Center, Cardiovascular and Metabolic Disease Core Research Support Center, Inje University, Busan, Korea
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (3) , C722-C735
SGLT2 inhibitors as modulators of mitochondrial ion transport and ER-mitochondria cross talk in diabetic cardiomyopathy
Diabetic cardiomyopathy (DCM) is a major complication of type 2 diabetes mellitus and a leading contributor to heart failure. A central feature of DCM is the disruption of mitochondrial bioenergetics and calcium homeostasis, processes that are tightly regulated through mitochondria-associated endoplasmic reticulum membranes (MAMs). These endoplasmic reticulum (ER)-mitochondria contact sites coordinate mitochondrial ion transport systems, including the mitochondrial calcium uniporter, Na + /Ca 2+ exchanger, and potassium channels, which collectively govern mitochondrial metabolism, redox balance, and cell survival. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as glucose-lowering agents, have recently demonstrated robust cardioprotective effects independent of glycemic control. Emerging evidence suggests that these benefits are partly mediated through the regulation of mitochondrial function and ER stress signaling. In this review, we discuss how SGLT2 inhibitors—particularly empagliflozin, canagliflozin, and dapagliflozin—modulate mitochondrial ion homeostasis, mitochondrial dynamics, and mitophagy in diabetic hearts. We further highlight their potential role in stabilizing ER-mitochondria communication by attenuating unfolded protein response signaling and restoring calcium balance at MAM interfaces. Finally, we explore the emerging concept that combining SGLT2 inhibitors with exercise may synergistically improve mitochondrial quality control and ER-mitochondria coupling, representing a promising pharmaco-lifestyle strategy for diabetic cardiomyopathy. Understanding how mitochondrial ion transport and organelle cross talk are modulated by SGLT2 inhibitors may provide new mechanistic insights and therapeutic opportunities for cardiometabolic diseases.
- 1 September 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (3) , C722-C735
Open AccessSGLT2 inhibitors as modulators of mitochondrial ion transport and ER-mitochondria cross talk in diabetic cardiomyopathy
Diabetic cardiomyopathy (DCM) is a major complication of type 2 diabetes mellitus and a leading contributor to heart failure. A central feature of DCM is the disruption of mitochondrial bioenergetics and calcium homeostasis, processes that are tightly regulated through mitochondria-associated endoplasmic reticulum membranes (MAMs). These endoplasmic reticulum (ER)-mitochondria contact sites coordinate mitochondrial ion transport systems, including the mitochondrial calcium uniporter, Na + /Ca 2+ exchanger, and potassium channels, which collectively govern mitochondrial metabolism, redox balance, and cell survival. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as glucose-lowering agents, have recently demonstrated robust cardioprotective effects independent of glycemic control. Emerging evidence suggests that these benefits are partly mediated through the regulation of mitochondrial function and ER stress signaling. In this review, we discuss how SGLT2 inhibitors—particularly empagliflozin, canagliflozin, and dapagliflozin—modulate mitochondrial ion homeostasis, mitochondrial dynamics, and mitophagy in diabetic hearts. We further highlight their potential role in stabilizing ER-mitochondria communication by attenuating unfolded protein response signaling and restoring calcium balance at MAM interfaces. Finally, we explore the emerging concept that combining SGLT2 inhibitors with exercise may synergistically improve mitochondrial quality control and ER-mitochondria coupling, representing a promising pharmaco-lifestyle strategy for diabetic cardiomyopathy. Understanding how mitochondrial ion transport and organelle cross talk are modulated by SGLT2 inhibitors may provide new mechanistic insights and therapeutic opportunities for cardiometabolic diseases.
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Mitochondrial Communications
- Vol. 4, 16-26
Mitochondrial reprogramming as a central driver of pancreatic ductal adenocarcinoma
- 1 January 2026
- Published by KEAI Publishing in Mitochondrial Communications
- Vol. 4, 16-26
Open AccessMitochondrial reprogramming as a central driver of pancreatic ductal adenocarcinoma